Scholarlink

<p>This retrospective study presents a 10-year-old male with multi-systemic venous thromboembolism (VTE) secondary to COVID-19, including right ventricular thrombus(40&#xa0;mm × 18&#xa0;mm), bilateral iliac vein thrombosis, pulmonary embolism, and renal vein thrombosis. The child presented with fever, abdominal pain, and elevated inflammatory markers (CRP 222.72&#xa0;mg/L, WBC 22.41 × 10<sup>⁹</sup>/L). Imaging confirmed extensive thrombi in the right ventricle, pulmonary arteries, and lower extremities. Anticoagulation with rivaroxaban (10&#xa0;mg QD) was initiated alongside anti-infective and anti-inflammatory therapies. Over a 3-year follow-up, thrombus burden significantly regressed, with D-dimer decreasing from 73 430&#xa0;µg/L to 290&#xa0;µg/L, and no recurrence or bleeding complications were observed. Coagulation parameters (PT, APTT) stabilized within therapeutic ranges. This case suggests the efficacy and safety of rivaroxaban in long-term management of multi-system VTE in pediatric patient, especially in cases of COVID-19-associated hypercoagulability. The primary clinical outcomes were the resolution of thrombus burden as evidenced by imaging and the absence of bleeding complications or recurrence during the follow-up period. The findings align with emerging evidence supporting direct oral anticoagulants (DOACs) in children, emphasizing individualized dosing and long-term management. Further studies are warranted to validate DOACs’ role in pediatric thrombosis, especially in the context of viral infections.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Rare pediatric multi-system thrombosis post-COVID-19: a three-year follow-up case report and narrative review on rivaroxaban for long-term management

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月9日

查看全文
  • Shiyi Zhu,
  • Xiaozhong Li,
  • Ruyue Chen,
  • Shuang Wu,
  • Lu Jiang,
  • Mengxia Li,
  • Luyao Huang,
  • Ningxun Cui

摘要

This retrospective study presents a 10-year-old male with multi-systemic venous thromboembolism (VTE) secondary to COVID-19, including right ventricular thrombus(40 mm × 18 mm), bilateral iliac vein thrombosis, pulmonary embolism, and renal vein thrombosis. The child presented with fever, abdominal pain, and elevated inflammatory markers (CRP 222.72 mg/L, WBC 22.41 × 10⁹/L). Imaging confirmed extensive thrombi in the right ventricle, pulmonary arteries, and lower extremities. Anticoagulation with rivaroxaban (10 mg QD) was initiated alongside anti-infective and anti-inflammatory therapies. Over a 3-year follow-up, thrombus burden significantly regressed, with D-dimer decreasing from 73 430 µg/L to 290 µg/L, and no recurrence or bleeding complications were observed. Coagulation parameters (PT, APTT) stabilized within therapeutic ranges. This case suggests the efficacy and safety of rivaroxaban in long-term management of multi-system VTE in pediatric patient, especially in cases of COVID-19-associated hypercoagulability. The primary clinical outcomes were the resolution of thrombus burden as evidenced by imaging and the absence of bleeding complications or recurrence during the follow-up period. The findings align with emerging evidence supporting direct oral anticoagulants (DOACs) in children, emphasizing individualized dosing and long-term management. Further studies are warranted to validate DOACs’ role in pediatric thrombosis, especially in the context of viral infections.